Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.
Tobias Hegelmaier, Jeremias Motte, Denise Walther et al.
✦ AI-curated · Sources linked
Case in brief
Three patients with severe, treatment-resistant myasthenia gravis (MG) were treated with autologous anti-CD19 CAR T cell therapy. All patients achieved rapid and sustained clinical remission for at least 19 months, allowing them to discontinue MG-specific immunotherapies. Despite persistent anti-AChR autoantibody titers, they experienced significant clinical and functional improvements, with manageable treatment-related adverse events.
Diagnostic / clinical pearl
Anti-CD19 CAR T cell therapy may provide a durable treatment option for patients with refractory myasthenia gravis, achieving remission even with persistent autoantibody presence.
Why it matters
This case series highlights the potential of CAR T cell therapy in managing autoimmune diseases like MG, suggesting a shift towards more effective long-term treatment strategies.